SCHEMBL30677266

SCHEMBL30677266

COc1cccc(-n2c(C)nc3c(Cl)nc(Cl)nc32)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ TSHR P16473 2/20 0.47
▸ HTT P42858 1/20 0.47
▸ THRB P10828 1/20 0.44
▸ LMNA P02545 2/20 0.43
▸ FYN P06241 1/20 0.42
▸ EPHB4 P54760 1/20 0.42
▸ MAPT P10636 2/20 0.41
▸ NR1H2 P55055 4/20 0.41
▸ NR1H3 Q13133 4/20 0.41
▸ YTHDC1 Q96MU7 1/20 0.40
▸ GAA P10253 3/20 0.39
▸ NOTUM Q6P988 1/20 0.39
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30677249 0.84 CYP1A2 (0.47) CYP1A2SMN1; SMN2TSHRHTTTHRB
SCHEMBL30677485 0.82 PI4KA (0.50) TSHRHTTMEN1ALDH1A1KMT2A
SCHEMBL30677377 0.76 XDH (0.57) TSHRHTTLMNAYTHDC1CYP2D6
SCHEMBL1272301 0.76 NR1H2 (0.65) CYP1A2SMN1; SMN2TSHRHTTTHRB
SCHEMBL30677385 0.75 GSK3B (0.45) SMN1; SMN2THRBLMNAMAPTMEN1
SCHEMBL31576372 0.75 GSK3B (0.45) SMN1; SMN2THRBLMNAMAPTMEN1
SCHEMBL4330834 0.74 CRHR1 (0.57) SMN1; SMN2TSHRHTTLMNAMAPT
SCHEMBL4325790 0.70 TP53 (0.47) CYP1A2SMN1; SMN2MAPTCYP2C19MEN1
SCHEMBL30677503 0.69 DPP4 (0.41) SMN1; SMN2HTTMAPTMEN1ALDH1A1
SCHEMBL28293678 0.69 ADORA3 (0.46) SMN1; SMN2TSHRHTTLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388582-A1 NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF ILDONG PHARMACEUTICAL CO LTD (KR) 2025-12-25 — — US disclosed
EP-4556476-A1 NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF Ildong Pharmaceutical Co., Ltd. (KR) 2025-05-21 — — EP disclosed
WO-2024014885-A1 NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF 일동제약(주) 2024-01-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388582-A1 NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF GBA1, PIKFYVE, MAN2B1 CYP1A2 3958/4885SMN1; SMN2 835/4885TSHR 3647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback